Chris Belmont, vice president and chief information officer, MD Anderson Cancer Center, says that health systems like Ochsner are using data to validate what they already know about certain patient cases.
Chris Belmont, vice president and chief information officer, MD Anderson Cancer Center, says that health systems like Ochsner are using data to validate what they already know about certain patient cases.
“For example, we’re monitoring patients in their home, so we’re providing them with devices so that we can stay connected with them after they leave. We know things that occur in the first 7 days, or actually first 14 days, are one of the big the reasons for readmissions,” says Mr Belmont. “The typical approach was to have someone—say from Home Health or someone call them and monitor them—but now we have devices that are collecting data more frequently.”
Mr Belmont suggests that instead of having someone manually go out to take patient information every few days, health systems can electronically “visit” patients as often as desired. For those patients managing chronic conditions such as high blood pressure, or health issues like obesity, electronic health monitoring can be more convenient.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL
January 27th 2025Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.
Read More